地址：武汉市洪山区光谷大道35号光谷总部国际时代 二期1栋1301
电话：18372041646
传真：18995651644
邮箱：sales@amyjet.com
Dendritics公司主要关注人类树突状细胞，希望找到能够促使CD34+造血前体细胞转化为树突状细胞（在GM-CSF和TNF-alpha存在的情况下）的细胞因子。在1992-2005年间，大量的研究使得研究者对人类树突状细胞的产生、细胞通路、C-type凝集素受体的功能及Toll-like受体的活性有了更深的理解。
DENDRITICS was started in 2005 by former members of SCHERING PLOUGH Laboratory for Immunological Research (LIR) in Dardilly, France. From their long experience at LIR, the team members of DENDRITICS have gathered complementary scientific and technological knowledge in different areas of immunology. The initial focus of LIR was in the biology of B lymphocytes, elaboration of human monoclonal antibodies, and in cytokine discovery (IL-3, IL-4, IL-7, IL-10, IL-17, GM-CSF) together with our colleagues of DNAX Research Institute in Palo Alto, California.
Our interest in cytokines led to the finding that human dendritic cells (DCs) could be generated in vitro from CD34+ hematopoietic progenitors cultured in the presence of GM-CSF and TNF-alpha.
The period from 1992 to 2005 saw the specialization of LIR in DC biology and was fuelled by a large-scale effort to discover and study the function of genes specifically expressed by these cells. This program led to a number of findings that contributed in particular to understanding the heterogeneity of DCs, the pathways regulating DC migration, the function of C-type lectin receptors in DCs and the activity of Toll-like receptors in DCs. Many novel genes were discovered through screening of cDNA libraries or through monoclonal antibodies raised against DCs.
<<更多详情请联系
艾美捷科技有限公司
全国服务热线：400-6800-868
邮箱：sales@amyjet.com
网站：www.amyjet.com
" data-original="http://phosphosolutions.51antibodies.com/template/company/xys_lvse/skin/image/lazyLoad.jpg" alt="Dendritics"> Dendritics
invivoCrown IV0104替换BioXCell BE0061
invivoCrown IV0107替换BioXCell BE0273
invivoCrown IV0114替换BioXCell BE0213
<艾美捷科技代理Trialtusbioscience品牌全系列产品
TriAltus Bioscience是一个致力于为推动人类健康前沿的科学家服务的品牌。当今的创新者在推进基因疗法、工程诊断、早期疾病检测以及药物发现等领域，都需要高纯度、高性能且随时可以扩展的酶，TriAltus正是为此而存在。TriAltus的核心是其专有的CLiM™（CL7/Im7）纯化平台，是一种基于亲和标签的突破性系统，能在单个色谱步骤中提供具有卓越纯度、活性和一致性的酶，重新定义了重组蛋白纯化的可能性。 使用CLiM™生产的每种酶都以严格的质量控制、批次间一致性和详细的分析证书（COA）为后盾，旨在满足监管机构要求的质量和文档标准，支持从发现到扩大规模的更平稳过渡。TriAltus Bioscience公司的产品包括：基因组酶、蛋白酶和其他酶。
▍Trialtusbioscience产品线
● 基因组酶：TriAltus的重组基因组酶不含标签，并使用专有的CLiM™亲和标签系统进行纯化，提供目录酶的定制缩放和配方，以满足特定研究需求，无论需要更高的浓度、独特的缓冲条件还是批量生产，都可以根据具体规格定制酶。
| 货号 | 品名 | 规格 | 产品描述 |
| 40-1212 | AapCas12b Protein | 20 μg | expressed in E. coli and features two C-terminal nuclear localization signals，enables the inactive nuclease to be guided to the specific double stranded DNA site. |
| 40-1220 | AapCas12b Protein | 100 μg | |
| 40-1225 | AapCas12b Protein | 500 μg | |
| 40-1320 | CRISPR-Cas9 Protein | 100 μg | used for genome editing with CRISPR technology. Recombinant Streptococcus pyogenes Cas9 ，expressed in Escherichia coli and features two nuclear localization signals |
| 40-1325 | CRISPR-Cas9 Protein | 500 μg | |
| 40-2414 | Phi29 DNA Polymerase | 3,000 Units | a highly processive, isothermal enzyme from Bacillus subtilis phage phi29 ，with a robust 3'→5' proofreading exonuclease function. |
| 40-2420 | Phi29 DNA Polymerase | 10,000 Units | |
| 40-2125 | TAT-CRE Recombinase | 500 μg | used for site-specific DNA recombination in mammalian cells,a fusion protein combining a nuclear localization sequence, HIV-TAT cell permeabilization peptide, and Cre recombinase. |
| 40-2130 | TAT-CRE Recombinase | 1 mg | |
| 40-2135 | TAT-CRE Recombinase | 5 mg |
● 蛋白酶和其他酶：例如为冷冻电镜生成蛋白质的实验室提供SUMO蛋白酶，去除相关标签后蛋白质可进行分析，反应高效、稳健，无需优化，客户对酶的性能和优质客户服务感到满意。
| 货号 | 品名 | 规格 | 产品描述 |
| 30-2130 | PreScission Protease | 1 mg | recognizes and cleaves the sequence LEVLFQ/GP to release the target protein from the Im7-bound CL7 tag |
| 30-2135 | PreScission Protease | 5 mg | |
| 30-2140 | PreScission Protease | 10 mg | |
| 30-2146 | PreScission Protease | 50 mg | |
| 30-2150 | PreScission Protease | 100 mg | |
| 30-1130 | SUMO Protease | 1 mg | releases target proteins from TriAltus’s Im7 resin，recognizes SUMO tertiary structure – not a specific amino acid sequence – to cleave and release the target protein from the Im7-bound CL7 tag. |
| 30-1135 | SUMO Protease | 5 mg | |
| 30-1140 | SUMO Protease | 10 mg | |
| 30-1146 | SUMO Protease | 50 mg | |
| 30-1150 | SUMO Protease | 100 mg |
invivoCrown IV0119替换BioXCell BE0004-1
invivoCrown IV0100替换BioXCell BE0146
invivoCrown IV0117替换BioXCell BE0223
KAMIYA公司旨在为生命科学和医疗机构提供高品质的创新的实验室研究和诊断工具。KAMIYA公司最早研发的产品是最前沿的用于信号转导研究的蛋白激酶抑制剂staurosporine（星形孢菌素）和K252a。1990年，KAMIYA成为美国第一家生产细胞凋亡研究的anti-Fas单克隆抗体的公司。如今，KAMIYA的产品线包括数千种人和动物临床前试验的生物标志物检测试试剂盒。此外,KAMIYA公司还为生命科学领域的研究着提供多种多样的酶抑制剂、单克隆抗体和多克隆抗体等产品，可用于研究细胞凋亡、耐药性、氧化、DNA损伤和修复、骨骼生物学、癌症、心脏病、炎症、肥胖症、糖尿病等研究。
KAMIYA公司K-ASSAY产品，用于胰岛素、血浆D-二聚体、凝血因子xiii、血浆FDP、血清/尿液 FPD、血清/尿液FDP-E、总IgE等指标的检测。KAMIYA现已发展成美国最大的脂质血清蛋白免疫分析试剂生厂商，为众多大型医院、医疗中心、临床实验室、临床参考实验室、科研机构、诊断试剂研发公司等机构提供优质的临床诊断试剂。
KAMIYA BIOMEDICAL COMPANY was founded by Kohji Kamiya in March of 1983 in Thousand Oaks, California and relocated to Seattle, Washington in 1996. Our company's purpose is supplying the life science and medical communities with innovative laboratory research and diagnostic tools of the highest quality. KAMIYA is an independent American company that serves worldwide markets.
<更多详情请联系
艾美捷科技有限公司
全国服务热线：400-6800-868
邮箱：sales@amyjet.com
网站：www.amyjet.com
< " data-original="http://phosphosolutions.51antibodies.com/template/company/xys_lvse/skin/image/lazyLoad.jpg" alt="Kamiya Biomedical"> Kamiya Biomedical invivoCrown IV0104替换BioXCell BE0061
地址：武汉市洪山区光谷大道35号光谷总部国际时代 二期1栋1301
电话：18771149750
传真：15172469628
邮箱：sales@amyjet.com
0.1597
